Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma

Kenji Inoue; Junji Inoue; Shiho Kunimatsu-Sanuki; Norie Nozaki; Kosuke Shimizu; Kyoko Ishida; Goji Tomita

doi:10.2147/OPTH.S271789

Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma

Clin Ophthalmol. 2020 Sep 30:14:2943-2949. doi: 10.2147/OPTH.S271789. eCollection 2020.

Authors

Kenji Inoue¹, Junji Inoue², Shiho Kunimatsu-Sanuki², Norie Nozaki³, Kosuke Shimizu⁴, Kyoko Ishida⁵, Goji Tomita^{1

5}

Affiliations

¹ Inouye Eye Hospital, Chiyoda-Ku, Tokyo, Japan.
² Nishikasai Inouye Eye Hospital, Edogawa-Ku, Tokyo, Japan.
³ Omiya Inouye Eye Clinic, Saitama-Shi, Saitama, Japan.
⁴ Sapporo Inouye Eye Clinic, Sapporo-Shi, Sapporo, Japan.
⁵ Department of Ophthalmology, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan.

Abstract

Purpose: To retrospectively evaluate the short-term efficacy of omidenepag isopropyl (EYBELIS 0.002%) by assessing its intraocular pressure (IOP)-lowering capability and safety in patients with normal-tension glaucoma (NTG).

Patients and methods: Fifty-four NTG patients (54 eyes) who were newly administrated with omidenepag isopropyl were enrolled in the study. The subjects comprised 22 men and 32 women, and the mean age of the subjects was 55.0 ± 14.1 years. The mean deviation value using the Humphrey visual field test program (30-2 SITA Standard) was -5.03 ± 3.38 dB. The following data were retrieved from the medical records and used for retrospective analyses: IOP at baseline 1-2 months and 3-4 months after administration. The frequency of non-responder patients who had less than 10% IOP reduction was evaluated. Patients were observed for adverse reactions and dropouts at each time point.

Results: IOP at baseline, after 1-2 months and after 3-4 months was 15.7 ± 2.6 mmHg, 13.5 ± 2.3 mmHg, and 13.6 ± 2.4 mmHg, respectively. There was a significant decrease in IOP after administration (p<0.0001). Eleven patients (22.4%) were non-responders. Adverse reactions occurred in 4 patients (7.4%), including conjunctival hyperemia in 3 patients (after 1 week, 2 weeks, and 1 month, respectively) and eye pain in 1 patient (after 1 month). Five patients (9.3%) dropped out of the study because of an adverse reaction in 3 patients, insufficient IOP reduction in 1 patient, and discontinuation of follow-up of 1 patient at our institution.

Conclusion: After administration of omidenepag isopropyl, IOP in patients with NTG was significantly decreased. However, adverse reactions occurred in 7.4% of patients.

Keywords: EP2 receptor agonist; adverse reactions; conjunctival hyperemia; intraocular pressure.